Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia

Blood

Volumn 129, Issue 11, 2017, Pages e26-e37

  Frismantas, Viktoras ^a   Dobay, Maria Pamela ^b   Rinaldi, Anna ^a   Tchinda, Joelle ^a   Dunn, Samuel H ^c   Kunz, Joachim ^d   Richter Pechanska, Paulina ^d   Marovca, Blerim ^a   Pail, Orrin ^a   Jenni, Silvia ^a   Diaz Flores, Ernesto ^e   Chang, Bill H ^f   Brown, Timothy J ^c   Collins, Robert H ^c   Uhrig, Sebastian ^g   Balasubramanian, Gnana P ^g   Bandapalli, Obul R ^d   Higi, Salome ^a   Eugster, Sabrina ^a   Voegeli, Pamela ^h   Delorenzi, Mauro ^b,i   Cario, Gunnar ^j   Loh, Mignon L ^e   Schrappe, Martin ^j   Stanulla, Martin ^k   Kulozik, Andreas E ^d   Muckenthaler, Martina U ^d   Saha, Vaskar ^l,m   Irving, Julie A ⁿ   Meisel, Roland ^o   Radimerski, Thomas ^p   Von Stackelberg, Arend ^g,q   Eckert, Cornelia ^g,q   Tyner, Jeffrey W ^f   Horvath, Peter ^r,s   Bornhauser, Beat C ^a   Bourquin, Jean Pierre ^a   more..

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h UNIVERSITY OF ZURICH   (Switzerland)

ⁱ UNIVERSITY OF LAUSANNE   (Switzerland)

^j UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^k HANNOVER MEDICAL SCHOOL   (Germany)

^l UNIVERSITY OF MANCHESTER   (United Kingdom)

^m Tata Medical Centre   (India)

ⁿ NEWCASTLE UNIVERSITY   (United Kingdom)

^o Department of Orthopedic Surgery   (Germany)

^p NOVARTIS PHARMA AG   (Switzerland)

^q CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^r INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^s UNIVERSITY OF HELSINKI   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; BARASERTIB; BLINATUMOMAB; BORTEZOMIB; CYTARABINE; DASATINIB; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; IDARUBICIN; IMATINIB; LUMINESPIB; MITOXANTRONE; NAVITOCLAX; PANOBINOSTAT; TEMSIROLIMUS; VENETOCLAX; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; EX VIVO STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA REMISSION; MALE; MOUSE; NONHUMAN; PERIODICITY; PRE B LYMPHOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TUMOR XENOGRAFT; CELL CULTURE; COCULTURE; DRUG RESISTANCE; MESENCHYMAL STROMA CELL; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; XENOGRAFT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELLS, CULTURED; COCULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; HETEROGRAFTS; HUMANS; MESENCHYMAL STROMAL CELLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 85015886035     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-09-738070     Document Type: Article

References (55)

1. Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood. 2012;120(14): 2807-2816.
2. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013; 381(9881):1943-1955.
3. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005-1015.
4. Holmfeldt L, Wei L, Diaz-Flores E, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45(3): 242-252.
5. Shochat C, Tal N, Bandapalli OR, et al. Gain-offunction mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med. 2011;208(5):901-908.
6. Hunger SP, Devaraj PE, Foroni L, Secker-Walker LM, Cleary ML. Two types of genomic rearrangements create alternative E2A-HLF fusion proteins in t(17;19)-ALL. Blood. 1994; 83(10):2970-2977.
7. Eckert C, Hagedorn N, Sramkova L, et al. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment. Leukemia. 2015;29(8):1648-1655.
8. Bader P, Kreyenberg H, von Stackelberg A, et al. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial. J Clin Oncol. 2015; 33(11):1275-1284.
9. Schrappe M, Hunger SP, Pui CH, et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med. 2012; 366(15):1371-1381.
10. Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012; 483(7391):570-575.
11. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603-607.
12. Gao H, Korn JM, Ferretti S, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med. 2015;21(11):1318-1325; advance online publication.
13. Wang K, Sanchez-Martin M, Wang X, et al. Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias. Leukemia. 2017;31(1):151-158.
14. Townsend EC, Murakami MA, Christodoulou A, et al. The Public Repository of Xenografts enables discovery and randomized phase II-like trials in mice. Cancer Cell. 2016;29(4):574-586.
15. Jones L, Carol H, Evans K, et al. A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program. Leukemia. 2016; 30(11):2133-2141.
16. Pemovska T, Kontro M, Yadav B, et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013; 3(12):1416-1429.
17. Pemovska T, Johnson E, Kontro M, et al. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature. 2015; 519(7541):102-105.
18. Tyner JW, Yang WF, Bankhead A III, et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res. 2013;73(1):285-296.
19. Geng H, Hurtz C, Lenz KB, et al. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 2015; 27(3):409-425.
20. Mihara K, Imai C, Coustan-Smith E, et al. Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol. 2003;120(5):846-849.
21. Boutter J, Huang Y, Marovca B, et al. Imagebased RNA interference screening reveals an individual dependence of acute lymphoblastic leukemia on stromal cysteine support. Oncotarget. 2014;5(22):11501-11512.
22. Bonapace L, Bornhauser BC, Schmitz M, et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest. 2010;120(4):1310-1323.
23. Schmitz M, Breithaupt P, Scheidegger N, et al. Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood. 2011;118(7): 1854-1864.
24. Mirkowska P, Hofmann A, Sedek L, et al. Leukemia surfaceome analysis reveals new disease-associated features. Blood. 2013; 121(25):e149-e159.
25. Den Boer ML, Harms DO, Pieters R, et al. Patient stratification based on prednisolone-vincristineasparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol. 2003; 21(17):3262-3268.
26. Hartwell KA, Miller PG, Mukherjee S, et al. Nichebased screening identifies small-molecule inhibitors of leukemia stem cells. Nat Chem Biol. 2013;9(12):840-848.
27. Manabe A, Coustan-Smith E, Behm FG, Raimondi SC, Campana D. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood. 1992;79(9):2370-2377.
28. Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest. 2007;117(4): 1049-1057.
29. Moorman AV. New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2016;101(4):407-416.
30. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202-208.
31. Luo FR, Yang Z, Camuso A, et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res. 2006;12(23):7180-7186.
32. McMillin DW, Negri JM, Mitsiades CS. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov. 2013;12(3):217-228.
33. Irving J, Matheson E, Minto L, et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;124(23): 3420-3430.
34. Hof J, Krentz S, van Schewick C, et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol. 2011;29(23):3185-3193.
35. Fischer U, Forster M, Rinaldi A, et al. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet. 2015;47(9):1020-1029.
36. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOPBFM ALL 2000 study. Blood. 2010;115(16): 3206-3214.
37. McComb S, Aguadé-Gorgorió J, Harder L, et al. Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL. Sci Transl Med. 2016;8(339):339ra70.
38. Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010; 376(9757):2009-2017.
39. Liedtke M, Cleary ML. Therapeutic targeting of MLL. Blood. 2009;113(24):6061-6068.
40. Alford SE, Kothari A, Loeff FC, et al. BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells. Cancer Res. 2015; 75(7):1366-1375.
41. Suryani S, Carol H, Chonghaile TN, et al. Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2014;20(17):4520-4531.
42. Peirs S, Matthijssens F, Goossens S, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014;124(25):3738-3747.
43. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440-446.
44. Chonghaile TN, Roderick JE, Glenfield C, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4(9):1074-1087.
45. Punnoose EA, Leverson JD, Peale F, et al. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. Mol Cancer Ther. 2016;15(5): 1132-1144.
46. Bicocca VT, Chang BH, Masouleh BK, et al. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell. 2012;22(5): 656-667.
47. Fallah-Tafti A, Foroumadi A, Tiwari R, et al. Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities. Eur J Med Chem. 2011; 46(10):4853-4858.
48. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341-354.
49. Foà R, Vitale A, Vignetti M, et al; GIMEMA Acute Leukemia Working Party. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521-6528.
50. Khaw SL, Suryani S, Evans K, et al. Venetoclax responses of pediatric ALL xenografts reveal MLL-rearranged leukemia. Blood. 2016;128(10): 1382-1395.
51. Ni Chonghaile T, Sarosiek KA, Vo TT, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011;334(6059):1129-1133.
52. Montero J, Sarosiek KA, DeAngelo JD, et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015;160(5):977-989.
53. Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106-1117.
54. Deenik W, Beverloo HB, van der Poel-van de Luytgaarde SC, et al. Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia. Leukemia. 2009;23(3): 627-629.
55. Zwaan CM, Rizzari C, Mechinaud F, et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. J Clin Oncol. 2013;31(19): 2460-2468.